What Is Pulling IperionX (ASX:IPX) Shares Down 14% Today?

Sonal Goyal

30 October 2026 11:55 AM AEDT

What Is Pulling IperionX (ASX:IPX) Shares Down 14% Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

IperionX (ASX:IPX) traded at $2.120, down 13.67%, during the Trading session on 30 October 2026.
The US Army awarded Task Order 2 with a base value of US$18.5 million, of which US$11.5 million was initially funded.
The company produced 1,500 fasteners and is scaling production for US customers.

IperionX Ltd (ASX:IPX) shares traded at $2.120 during the trading session on 30 October 2026, down 13.67%. The company is a titanium metal and components Business listed on Nasdaq and the ASX. Its September 2026 Quarterly Report was released on 29 October 2026, one day before the share move. The report covered defence contracts, production scaling and customer testing, and it is discussed separately from the share move.

Latest Development: Quarterly Report (29 October 2026)

The US Army awarded IperionX Task Order 2 under its US$99 million SBIR Phase III IDIQ contract. The base value is US$18.5 million, with US$11.5 million initially funded, and scoped Options bring the total potential value to US$25.4 million.

The company said it produced 1,500 fasteners and that production is scaling for US customers. Components for US Navy pump contractors are undergoing final customer testing to support commercial-scale orders. A follow-on purchase order was also secured from the US Army Ground Vehicle Systems Center.

Acquisition and Capacity

The company completed a US$3 million Acquisition of the adjacent Atlas critical minerals property. It also reported new sintering capacity at its Elnik facility, intended to support larger follow-on production orders across US Army ground combat platforms.

Company Background

IperionX is a titanium metal and components company listed on Nasdaq and the ASX. Its activities include the Elnik sintering facility, the Atlas critical minerals acquisition and work supplying titanium components to US defence programs, including the US Army and US Navy contractors. The company's business therefore combines Mining activity with the production of finished components.

Reporting Scope and Limitations

The quarterly report describes contract values, funding and production activity. Task order values include options that are not yet committed, and the report does not give Revenue recognised to date. The company's technical study figures are presented as referenced results from earlier announcements.

Sector Context

Titanium components for defence applications are procured through government contracts with staged funding, and suppliers are judged on qualification, production capacity and the conversion of prototype orders into production orders. The company's announcements emphasise these stages.

Risks

Only US$11.5 million of the US$18.5 million base value was initially funded, and the remaining options depend on further government decisions. Customer testing has not yet led to commercial-scale orders. The company's production scaling and new capacity require operating execution.

What Lies Ahead

The company expects its components to complete final customer testing for US Navy pump contractors and to support larger follow-on orders from the US Army. Future quarterly reports will show whether these orders convert into production.

Final Word

IperionX fell 13.67 per cent during the trading session on 30 October 2026, one day after a quarterly report describing a US Army task order, new production capacity and customer testing. The conversion of testing and prototype orders into production orders will be the next measure to follow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.